Faron Pharmaceuticals Limited (AIM:FARN)’s founders Markku Jalkanen and Sirpa Jalkanen have been selected as finalists for the 2024 European Inventor Award in the SMEs category.
Their nomination comes in recognition of their work on bexmarilimab, an investigational immunotherapy aimed at enhancing clinical outcomes in cancer treatment by targeting the Clever-1 receptor on macrophages, promoting anti-tumour immunity.
In addition to the technical accolade, the public is invited to vote in the ‘Popular Prize’, which goes to the shortlisted inventor with the most votes.
The winners in each category, and the winner of the Popular Prize, will be announced at the online award ceremony on 9 July.
"It is an honour to be recognised by the European Patent Office and nominated for this prestigious award,” said Markku Jalkanen. “The continued progress of our ambitious bexmarilimab development program and the exceptional data we are seeing in the ongoing Phase I/II BEXMAB trial, reaffirms our belief in the potential of bexmarilimab to change the treatment paradigm.
“These highly significant findings provide us with continued confidence that bexmarilimab can improve the quality of life of those suffering from these aggressive hematological cancers, where there are limited options available for future therapy."
